stock downgrade

The investment bank said that while Twist's biopharma and DNA-based data storage businesses offer upside, the timelines for generating revenues are unclear.

The investment bank said it expects demand for Fulgent's COVID-19 testing to decline over the next two years.

The investment bank also moved the company's stock price target to $45 from a prior target of $25 and noted several recent acquisitions by Invitae.

The GenomeWeb Index outperformed the Dow Jones, the Nasdaq, and the Nasdaq Biotechnology Index, which all fell in September.

The investment firm said that Grail's revenue trajectory is uncertain, and given the firm's operating loss, it will significantly dilute Illumina's earnings.

OncoCyte will cease further development of a liquid biopsy test that used an immune system interrogation approach to clarify whether patients’ lung nodules are benign.

The GenomeWeb Index fell 2 percent, outperforming the Nasdaq Biotechnology Index but doing worse than the Dow Jones and the Nasdaq.

The GenomeWeb Index vastly outperformed the Dow Jones and the Nasdaq Biotechnology Index this month, while slightly underperforming the Nasdaq.

The investment bank gave PerkinElmer an Outperform rating with a $114 stock price target and Hologic an In Line rating with a $55 stock price target.

The investment banking firm has lowered its rating for shares of the sequencing giant, but raised its price target to $340 from $330.